MetLife Investment Management’s ClearPoint Neuro CLPT Stock Holding History

MetLife Investment Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296K	Buy	16,564 +1,304	+9%	+$16.3K	﹤0.01%	2212
2026 Q1	$139K	Hold	15,260	–	–	﹤0.01%	2392
2025 Q4	$209K	Buy	15,260 +4,002	+36%	+$74.2K	﹤0.01%	2252
2025 Q3	$245K	Sell	11,258 -4,567	-29%	-$53.8K	﹤0.01%	2202
2025 Q2	$189K	Buy	+15,825	New	+$199K	﹤0.01%	2231
2024 Q2	–	Sell	-12,254	Closed	-$70.9K	–	2889
2024 Q1	$83.3K	Hold	12,254	–	–	﹤0.01%	2618
2023 Q4	$83.2K	Hold	12,254	–	–	﹤0.01%	2681
2023 Q3	$61.4K	Hold	12,254	–	–	﹤0.01%	2800
2023 Q2	$88.7K	Buy	+12,254	New	+$104K	﹤0.01%	2746
2021 Q4	–	Sell	-7,721	Closed	-$137K	–	2506
2021 Q3	$137K	Hold	7,721	–	–	﹤0.01%	2293
2021 Q2	$147K	Buy	+7,721	New	+$149K	﹤0.01%	2334

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

MetLife Investment Management's CLPT Position: Q2 2026 in Review

MetLife Investment Management increased its ClearPoint Neuro (CLPT) stake by 8.5% in Q2 2026, buying an estimated $16.3K and bringing the position to 16,564 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

MetLife Investment Management first reported a position in CLPT in Q2 2021 and has held it in 11 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

MetLife Investment Management held 16,564 shares of ClearPoint Neuro worth $296K as of Q2 2026.
MetLife Investment Management bought 1,304 ClearPoint Neuro shares in Q2 2026, an estimated $16.3K.
ClearPoint Neuro made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2212 holding.
MetLife Investment Management first reported a position in ClearPoint Neuro in Q2 2021 and has held it in 11 quarters since.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.